

## Special Issue

# Antibiotics and Infectious Respiratory Diseases, 2nd Edition

### Message from the Guest Editors

Dear Colleagues. Infectious respiratory diseases (IRD) continue to be among the leading causes of morbidity and mortality globally, and in the age of the COVID-19 pandemic. They can be caused by viruses, bacteria, parasites, or opportunistic infections; nevertheless, indiscriminate antibiotic usage in their treatment has resulted in the development of antimicrobial resistance. The effective management of respiratory infectious illnesses in order to lessen their burden and avoid antibiotic misuse has become a major therapeutic and public health concern. Manuscripts addressing the following topics are also welcome:

- Antimicrobial resistance and bacterial host resistance;
- New antibiotics for MDR infection;
- HAP (hospital-acquired pneumonia), VAP (ventilator-associated pneumonia), and CAP (community-acquired pneumonia) are the three types of pneumonia;
- Nontuberculous mycobacteria (NTM) and tuberculosis;
- SARS CoV2 interstitial pneumonia and viral pneumonia;
- Antimicrobial resistance and antimicrobial prescription education;
- Infection with pneumonia in immunocompetent and immunocompromised people.

### Guest Editors

Prof. Dr. Francesco Di Gennaro

Dr. Fabrizio Palmieri

Dr. Gina Gualano

### Deadline for manuscript submissions

30 September 2025



## Antibiotics

an Open Access Journal  
by MDPI

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/si/142870](https://mdpi.com/si/142870)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)